Sellas Life Sciences (SLS) rose 1% overnight heading into Tuesday after winning a Stocktwits retail sentiment poll with 50% of 3,400 votes. SLS stock fell 7% on Monday to $13.94, while Ondas Holdings drew 24%, ImmunityBio 18%, and PayPal 8% in the same poll. Retail traders are focused on the company's Phase 3 Regal trial of GPS in acute myeloid leukemia, which has reached 78 of the 80 events needed to trigger final analysis.
Stocktwits Poll Shows SLS Leading Retail Sentiment
A Stocktwits poll asking users which trending stock they were most bullish on showed Sellas leading with 50% of 3,400 votes. Ondas Holdings followed with 24%, ImmunityBio drew 18%, and PayPal received 8%. Sentiment on the platform has dipped into the 'bullish' range from 'extremely bullish' levels a day ago amid a 131% jump in 24-hour message volumes.
Phase 3 Regal Trial Reaches 78 of 80 Events
The retail focus centers on Sellas' Phase 3 Regal trial of GPS (galinpepimut-S) in acute myeloid leukemia (AML). The study has reached 78 of the 80 events needed to trigger final analysis. The next two events—data lock and topline results—are the key milestones traders are watching.
CEO Stergiou Posts Optimistic LinkedIn Message
CEO Angelos Stergiou posted a Fourth of July LinkedIn message thanking "clinical investigators, research sites, collaborators, strategic partners, and shareholders" for their "trust" and "partnership." He added that he was "incredibly optimistic about the future." Investors have also reviewed updated executive severance and change-of-control arrangements. Stergiou's amended agreement shifts certain change-of-control severance payments to a lump sum, while CFO John Burns and Chief Development Officer Dragan Cicic would receive salary, bonus, COBRA reimbursement and full equity acceleration under qualifying change-of-control terminations.
SLS Market Value Climbs to Over $1.5 Billion
Sellas' market value has climbed from $73 million at the start of 2024 to more than $1.5 billion by mid-2026. The company ended the first quarter with $107.1 million in cash and raised another $28.7 million through warrant exercises in April and May. Shareholders recently approved a 20 million-share increase to the company's 2023 Equity Incentive Plan. Stergiou was awarded 1.065 million restricted stock units vesting over four years, raising his ownership to 1.76 million shares. SLS stock surged 542% over the past year.
FAQ
What percentage of votes did SLS receive in the Stocktwits poll?
SLS received 50% of 3,400 votes in a Stocktwits poll asking which trending stock users were most bullish on, ahead of Ondas Holdings at 24%, ImmunityBio at 18%, and PayPal at 8%.
How many events has the Phase 3 Regal trial reached?
The Phase 3 Regal trial of GPS in acute myeloid leukemia has reached 78 of the 80 events needed to trigger final analysis.
What did CEO Angelos Stergiou say in his Fourth of July LinkedIn post?
CEO Angelos Stergiou thanked clinical investigators, research sites, collaborators, strategic partners, and shareholders for their trust and partnership, and said he was "incredibly optimistic about the future."
